Cancer medicines

Alpelisib

Alpelisib

A targeted therapy for selected PIK3CA-mutated breast cancers.

Sources checked · Introductory guide

On this page

How it works

It inhibits PI3K signaling to limit cancer cell growth.[3]

Where it is used

Used with fulvestrant after endocrine therapy in selected PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancers.[1]

Key safety points

Monitor for high glucose, severe rash and diarrhea. Plan glucose checks; report marked thirst, frequent urination, confusion or blistering rash immediately.[2]

Questions for your care team

  • What are my PIK3CA result, glucose monitoring plan and contact thresholds?

Sources and scope

Source documents are in English.

Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.

  1. NCI · Alpelisib (opens in a new tab)
  2. MedlinePlus · Alpelisib (opens in a new tab)
  3. NCI Drug Dictionary · Alpelisib (opens in a new tab)

General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.

Related entries

Alpelisib | Cancer Encyclopedia | My Chemo Diary